Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand
NCT00433030 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2816
Last updated 2018-03-20
Summary
Since 2004, the Thai Ministry of Public Health has massively scaled up antiretroviral treatment programs to provide therapy to more than 80,000 patients with partial support of the Global Fund to fight AIDS, Tuberculosis and Malaria (GFATM).
As access to HIV care continues to expand under the universal health coverage system, it is important to document and analyze the efficacy, tolerance, toxicity and acceptability of antiretroviral therapy within pilot treatment programs, to provide evidence based feedback and recommendations to the national program and policy makers.
Conditions
- HIV Infections
Sponsors & Collaborators
- collaborator OTHER
-
Ministry of Health, Thailand
collaborator OTHER_GOV -
Institut de Recherche pour le Developpement
lead OTHER_GOV
Principal Investigators
-
Gonzague JOURDAIN, MD, PhD · Institut de Recherche pour le Developpement
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-01-31
- Primary Completion
- 2018-02-28
- Completion
- 2018-02-28
Countries
- Thailand
Study Locations
More Related Trials
-
Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load
NCT00454337 ·Status: COMPLETED ·Phase: PHASE3
-
Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)
NCT01307124 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Explore Reconstitution of Immunity in Patients With Advanced HIV-1-infection
NCT01296373 ·Status: COMPLETED
-
Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care
NCT01900080 ·Status: UNKNOWN ·Phase: NA
-
A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
NCT01213316 ·Status: COMPLETED
-
Viral Suppression After Analytic Treatment Interruption in Thai Patients Who Initiated Highly Active Antiretroviral Therapy During Acute HIV Infection
NCT02614950 ·Status: COMPLETED ·Phase: NA
-
Preliminary Study of Early, Primary HIV Infection in a High Risk Cohort
NCT00989144 ·Status: COMPLETED
-
LA PrEP Impact and Cost-effectiveness (TEAMS)
NCT05774548 ·Status: RECRUITING ·Phase: NA
-
Observational Study of Effect of Radiation Therapy to Immuno Status in HIV-cancer Patients
NCT01546376 ·Status: UNKNOWN
-
A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection
NCT03563742 ·Status: TERMINATED ·Phase: PHASE3
-
Post Analytic Treatment Interruption Study
NCT02761200 ·Status: RECRUITING
-
Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)
NCT05312918 ·Status: UNKNOWN
-
Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD
NCT04311944 ·Status: UNKNOWN ·Phase: NA
-
Optimised Electronic Patient Records to Improve Clinical Monitoring of HIV-positive Patients in Rural South Africa
NCT05071573 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of PrEP-30: a Demonstration Project of Pre-exposure Prophylaxis for MSM and Other High-risk Group Clients at the Thai Red Cross Anonymous Clinic
NCT02437981 ·Status: ENROLLING_BY_INVITATION
-
Switching From PI to RALtegravir in HIV Stable Patients
NCT00528892 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
NCT03631732 ·Status: COMPLETED ·Phase: PHASE3
-
Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection
NCT01844310 ·Status: UNKNOWN ·Phase: NA
-
ALternative TEnofovir Dosing in Adults With Moderate Renal Function Impairment
NCT01671982 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy
NCT01338025 ·Status: TERMINATED ·Phase: PHASE4
-
Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children
NCT01225406 ·Status: COMPLETED
-
Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery
NCT00562510 ·Status: TERMINATED ·Phase: PHASE3
-
A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
NCT01709084 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
NCT00515827 ·Status: COMPLETED ·Phase: PHASE2
-
HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label
NCT04513626 ·Status: RECRUITING ·Phase: PHASE2